Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegozafermin in NASH with fibrosis
NCT04929483Phase 2Completed
- Sponsor
- 89bio
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Carrier/Scaffold Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pegozafermin in Nonalcoholic steatohepatitis (NASH) (6 arms), sponsored by 89bio. Primary endpoints: Histological Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis at 24 weeks and Improvement of Fibrosis ≥1 Stage Without Worsening of NASH at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
pegozafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04929483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929483.